NCT00930163View on ClinicalTrials.gov

A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids

PHASE2CompletedINTERVENTIONAL

Enrollment

218

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

July 31, 2010

Study Completion Date

September 30, 2010

Conditions

Asthma

Interventions

DRUG

lebrikizumab (MILR1444A)

Subcutaneous repeating dose

DRUG

placebo

Subcutaneous repeating dose

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY

NCT00930163 - A Study of Lebrikizumab (MILR1444A) in Adult Patients With Asthma Who Are Inadequately Controlled on Inhaled Corticosteroids | Biotech Hunter | Biotech Hunter